TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04561908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transseptal puncture with Brockenbrough-needle
Description: Conventional transseptal puncture with Brockenbrough-needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microguidewire-assisted transseptal puncture
Description: Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
Study: NCT03761238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbent Recirculating System
Description: MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
Study: NCT04322396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Hydroxychloroquine
Study: NCT03996200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIject CS627 implant
Description: MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye.
Study: NCT03755141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herzuma
Description: Herzuma + Treatment of Physician's Choice
Study: NCT04338711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution
Study: NCT02883816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of lung function
Description: measurement of lung volumes and flow rates of bronchial
Study: NCT02147041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG(Epigallocatechin Gallate)
Description: 500mg, three times a day, duration:12 weeks
Study: NCT04338711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tofacitinib modified release (MR)
Description: Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution
Study: NCT03160963

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat

Intervention type: OTHER
Intervention: Power Testing
Description: Chair stand, vertical jump, computerized squat
Study: NCT00052845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Description: 280 mg PO tid Days 1-5 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exisulind
Description: Two 125 mg capsules PO bid Days 1-21 of ea cycle
Study: NCT04151147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (Test group)
Description: The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Concentrated Growth Factor (Control group)
Description: Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
Study: NCT02958826

Intervention type: OTHER
Intervention: Questionnaire
Description: Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.

Intervention type: OTHER
Intervention: Questionnaire
Description: Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
Study: NCT01691027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-motor training
Description: Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
Study: NCT03591263

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
Study: NCT02446015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYSTANE® ULTRA Lubricant Eye Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSTANE® ULTRA Lubricant Eye Drops
Study: NCT04179799

Intervention type: DEVICE
Intervention: Diaphragm Pacing
Description: Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
Study: NCT03761238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment (SMT)
Description: Patient management and standard medical treatment (SMT) as specified in the study protocol.
Study: NCT02262702

Intervention type: DRUG
Intervention: Paracetamol 665 mg
Description: Paracetamol 665 mg tablet

Intervention type: DRUG
Intervention: Paracetamol 500 mg
Description: Paracetamol 500 mg tablet
Study: NCT02581215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
Study: NCT02277925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polytetrafluoroethylene
Description: Suture used to attach mesh during sacral colpopexy surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydioxanone
Description: Suture used to attach mesh during sacral colpopexy surgery
Study: NCT00705367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion, Intravenous, single dose, Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Infusion, Intravenous, 30mg/kg, single dose, Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
Study: NCT00328458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (epothilone B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (epothilone B)
Study: NCT00491582

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Growth hormone replacement therapy in growth hormone deficient patients only.
Description: Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
Study: NCT04064762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
Study: NCT02317848

Intervention type: OTHER
Group type: OTHER
Intervention: polygraphy and ECG
Description: polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
Study: NCT02139865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30% 1RM
Description: Participant exercises using a protocol tailored at 30% of their 1RM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 80% 1RM
Description: Participant exercises using a protocol tailored at 80% of their 1RM
Study: NCT01928901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Sinupret

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Sinupret

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Bronchipret

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Bronchipret

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Sinupret Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Sinupret Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Bronchipret Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Bronchipret Placebo
Study: NCT02013297

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT treatment
Description: For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy.
Study: NCT02413827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and ipilimumab
Description: Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg.
Study: NCT04521985

Intervention type: PROCEDURE
Intervention: thoracolumbar kyphosis surgery
Description: patients receiving surgery or not
Study: NCT00730080

Intervention type: DRUG
Intervention: Sapropterin (Kuvan)
Description: 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study: NCT01009606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual strategy
Description: Usual strategy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified strategy
Description: Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
Study: NCT00546000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% lotion
Description: Daily applications
Study: NCT01267305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5mg IH qd(8AM) after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5mg IH qd(8AM) after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH qd(8AM) after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH qd(8AM) after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH q12h(8Am,8Pm) after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH q12h(8Am,8Pm) after operation
Study: NCT01128244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Subjects will receive vitamin B6 supplementation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of labeled serine, methionine and leucine
Description: Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
Study: NCT02611843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Web CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Managed Web CBT
Study: NCT03454607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREE robot
Description: FREE robot to hold endoscope
Study: NCT04472455

Intervention type: DIAGNOSTIC_TEST
Intervention: HRME

Intervention type: DIAGNOSTIC_TEST
Intervention: HRME

Intervention type: DIAGNOSTIC_TEST
Intervention: HRME
Study: NCT00858208

Intervention type: DRUG
Intervention: pegaptanib sodium
Description: pegaptanib sodium intravitreal injection every 6 weeks for 2 years
Study: NCT02444052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Puros Cancellous Allograft
Description: Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Biocare Creos Cancellous Allograft
Description: Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
Study: NCT04276519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen
Description: Opening of the mechanical interface of the nerve root, neurodynamics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen
Description: Opening of the mechanical interface of the nerve root, neurodynamics
Study: NCT02413827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
Description: Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC.
Study: NCT01919658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
Study: NCT01467232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
Study: NCT03577431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arTreg-CSB
Description: Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol.
Study: NCT02182375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Study: NCT01679275

Intervention type: OTHER
Intervention: measuring cerebral oxygenation
Study: NCT03995381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Shared decision making with decision aids
Study: NCT04333810

Intervention type: DEVICE
Intervention: Whoop strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).

Intervention type: DEVICE
Intervention: Whoop strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
Study: NCT01474642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Cisplatin(XP)
Description: Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Paditaxel(XG)
Description: Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks